UroGen Pharma Ltd.
URGN
$24.38
-$4.08-14.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.87% | -49.51% | -35.80% | -44.19% | -8.20% |
| Total Depreciation and Amortization | 140.23% | 126.62% | 41.60% | -27.83% | -35.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.99% | -44.60% | -20.03% | 60.41% | -6.73% |
| Change in Net Operating Assets | -54.73% | 111.66% | 50.90% | 105.06% | -515.52% |
| Cash from Operations | -52.80% | -67.70% | -32.42% | -4.79% | -59.92% |
| Capital Expenditure | 9.38% | -67.86% | -- | -105.36% | 4.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 129.52% | 136.28% | -291.74% | 638.06% | -21,388.22% |
| Cash from Investing | 129.41% | 136.76% | -292.06% | 634.39% | -26,720.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.28% | -99.64% | -99.94% | 77.50% | -77.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -99.98% | -- | -- | -100.00% |
| Cash from Financing | -79.11% | -99.70% | -99.94% | 77.50% | -65.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.26% | -112.56% | -286.48% | 293.72% | -195.59% |